Idorsia Ltd.
4.52
EUR
-0.03
(-0.66%)
ISIN
CH0363463438
Return %
Stock
S&P 500
1Y
13.32
14.20
3Y
-75.72
81.12
5Y
-75.72
68.34
Capital Structure
CHF
•
in mil. unless spec.Working Capital
CHF
•
in mil. unless spec.Growth Rates
CHF
•
in mil. unless spec.Quarterly Revenue
CHF
•
in mil. unless spec.Quarterly Earnings Per Share
CHF
•
in mil. unless spec.Quarterly Dividends Per Share
CHF
•
in mil. unless spec.Company Description
- CEO
- Roland Wandeler
- Full Time Employees
- 487
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- Hegenheimermattweg 91 Allschwil BL Switzerland 4123
- IPO Date
- Jun 16, 2017
- Website
- idorsia.com
- Similar Companies
- Business
- Idorsia Ltd. is a biopharmaceutical company focused on innovative prescription medicines for unmet medical needs, with headquarters in Allschwil, Switzerland, founded in 2017 as a spin-off of Actelion and listed on the SIX Swiss Exchange (Ticker: IDIA). The company develops, manufactures, and markets late-stage pharmaceutical therapies across multiple therapeutic areas, including cardiometabolic, central nervous system, immunology, and oncology markets, and pursues global commercialization through direct subsidiaries and strategic partnerships. Main products and services: research and development for novel small molecules and biologics; clinical development services and phase-appropriate translational research; regulatory submissions and global product approvals; manufacturing of clinical and commercial drug substances and finished dosage forms; commercial sales and marketing of approved therapies; life-cycle management, post-approval studies, and pharmacovigilance; collaboration and licensing agreements with biotechnology and pharmaceutical partners; portfolio management across specialty medicines, with a focus on patients with high unmet need; digital health and data-driven insights to support patient access and outcomes. Latest major company changes: enters strategic partnerships and licensing arrangements to expand pipeline and global reach; completes funding announcements and equity transactions to support late-stage development; advances new product candidates into pivotal trials and supports regulatory submissions in key markets; implements organizational restructurings and efficiency programs to optimize operations and cost structures; expands geographic footprint through new market approvals and commercial launches in Europe, the Americas, and Asia-Pacific. Industry and business segments: biopharmaceuticals, specialized medicines, and clinical development services; therapeutic areas include neurology, immunology, metabolic disorders, cardiovascular diseases, and oncology; revenue through product sales, collaboration and licensing revenue, and development funding; focus on rare and high-need conditions; strategic collaborations with global pharmaceutical partners. Geographic operations: operates internationally with commercial activities in Europe, North America, Asia-Pacific, and other regions; maintains manufacturing and development facilities in Switzerland and selected alliance sites; distribution through regional affiliates and distributors to multiple countries. Founding year and headquarters location: founded in 2017 as a spin-off of Actelion; headquartered in Allschwil, Switzerland. Subsidiaries/parent relationships: independent publicly traded company with subsidiaries and regional affiliates supporting research, development, and commercialization; maintains strategic partnerships and licensing agreements with third-party organizations to expand its pipeline and market access.
Company News
New analysis of Idorsia’s aprocitentan demonstrates significant and sustained reduction in albuminuria in patients with uncontrolled / resistant hypertension
Santhera schlägt Dr. Srishti Gupta als neues Mitglied des Verwaltungsrats
Santhera Proposes Dr. Srishti Gupta as New Member of the Board of Directors
Idorsia’s daridorexant delivers outstanding results in a Phase 2 study in children with insomnia disorder
Clear route to registration positions lucerastat as the potential first oral therapy for all patients with Fabry disease
Idorsia's treatment for insomnia disorder wins the inaugural Prix Galien Bridges Award in the ‘Best Biotechnology & Pharmaceutical Product' category